Tagged as: Sanofi’s Lantus®

PTAB Issues Final Written Decisions Finding Two Of Sanofi’s Lantus Patents Invalid

Yesterday, December 12, 2018, the Board issued Final Written Decisions finding Claims 1-25 of U.S. Patent No. 7,476,652 (IPR2017-01526) and Claims 1-20 of U.S. Patent No. 7,713,930 (IPR2017-01528) unpatentable as obvious over the prior art.  IPR2017-01526 and IPR2017-01528 were two of a number of IPR petitions filed by Mylan against…

Read More